Scibase AB Cash Flow Conversion Efficiency

Latest as of March 2026: -0.457x

Scibase AB cash flow conversion efficiency. Based on the latest financial reports, Scibase AB (SCIB) has a cash flow conversion efficiency ratio of -0.457x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-26.57 Million ≈ $-2.86 Million USD) by net assets (Skr58.11 Million ≈ $6.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Scibase AB (2012–2025)

Cash flow conversion efficiency of Scibase AB from 2012 to 2025. This chart illustrates how Scibase AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Scibase AB (SCIB) stock price for real-time trading data and today's change.

Scibase AB Cash Flow Conversion Ratio Explained

Scibase AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Scibase AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Scibase AB ranked by their cash flow conversion efficiency. Also see SCIB stock market capitalisation for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Riley Gold Corp
V:RLYG
-0.026x
Sebata Holdings Ltd
JSE:SEB
0.031x
VOGO SA
PA:ALVGO
0.133x
Ihlas Gazetecilik AS
IS:IHGZT
-0.003x
ASIASOFT CORP.-NVDR-05
F:5ASA
0.039x
Mg Internation
PA:ALMGI
-0.026x
Chibougamau Independent Mines Inc
V:CBG
0.012x
Welcron Hantec Co.Ltd
KQ:076080
-0.066x

Annual Cash Flow Conversion Efficiency for Scibase AB (2012–2025)

The table below shows the annual cash flow conversion efficiency of Scibase AB from 2012 to 2025. Review SCIB free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Skr6.66 Million
≈ $716.29K
Skr-84.58 Million
≈ $-9.10 Million
-12.707x -711.59%
2024-12-31 Skr36.65 Million
≈ $3.94 Million
Skr-57.38 Million
≈ $-6.18 Million
-1.566x -29.68%
2023-12-31 Skr43.06 Million
≈ $4.63 Million
Skr-51.98 Million
≈ $-5.59 Million
-1.207x +31.48%
2022-12-31 Skr25.24 Million
≈ $2.72 Million
Skr-44.47 Million
≈ $-4.79 Million
-1.762x -215.78%
2021-12-31 Skr70.80 Million
≈ $7.62 Million
Skr-39.50 Million
≈ $-4.25 Million
-0.558x +22.78%
2020-12-31 Skr46.86 Million
≈ $5.04 Million
Skr-33.86 Million
≈ $-3.64 Million
-0.723x +39.05%
2019-12-31 Skr32.01 Million
≈ $3.45 Million
Skr-37.96 Million
≈ $-4.08 Million
-1.186x -126.10%
2018-12-31 Skr71.48 Million
≈ $7.69 Million
Skr-37.48 Million
≈ $-4.03 Million
-0.524x -37.36%
2017-12-31 Skr115.72 Million
≈ $12.45 Million
Skr-44.18 Million
≈ $-4.75 Million
-0.382x -47.93%
2016-12-31 Skr185.41 Million
≈ $19.95 Million
Skr-47.85 Million
≈ $-5.15 Million
-0.258x -61.43%
2015-12-31 Skr291.42 Million
≈ $31.36 Million
Skr-46.59 Million
≈ $-5.01 Million
-0.160x +85.92%
2014-12-31 Skr32.65 Million
≈ $3.51 Million
Skr-37.08 Million
≈ $-3.99 Million
-1.136x -20.76%
2013-12-31 Skr36.18 Million
≈ $3.89 Million
Skr-34.03 Million
≈ $-3.66 Million
-0.940x -161.14%
2012-12-31 Skr-23.69 Million
≈ $-2.55 Million
Skr-36.44 Million
≈ $-3.92 Million
1.538x --

About Scibase AB

ST:SCIB Sweden Medical Devices
Market Cap
$13.42 Million
Skr124.75 Million SEK
Market Cap Rank
#26158 Global
#535 in Sweden
Share Price
Skr12.20
Change (1 day)
-2.01%
52-Week Range
Skr0.21 - Skr50.80
All Time High
Skr50.80
About

SciBase Holding AB (publ), a medical technology company, develops and commercializes point-of-care platforms for skin health management in Europe, the United States, North America, Asia, Oceania, and internationally. It operates through Skin Cancer and Skin Barrier Assessment segments. The company offers Nevisense and Nevisense Go point-of-care platforms to detect melanoma and non-melanoma skin c… Read more